| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,897 |
4,183 |
$614K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
6,258 |
5,470 |
$561K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,165 |
985 |
$213K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
964 |
780 |
$166K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,911 |
1,698 |
$125K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
7,002 |
5,395 |
$48K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
7,294 |
5,884 |
$26K |
| 87400 |
|
461 |
403 |
$21K |
| 71046 |
Radiologic examination, chest; 2 views |
796 |
698 |
$17K |
| 71045 |
Radiologic examination, chest; single view |
2,495 |
2,136 |
$17K |
| G0378 |
Hospital observation service, per hour |
54 |
40 |
$14K |
| 70450 |
Computed tomography, head or brain; without contrast material |
496 |
442 |
$11K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,049 |
2,570 |
$10K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
266 |
249 |
$8K |
| 84484 |
|
2,293 |
1,754 |
$7K |
| 81001 |
|
2,083 |
1,751 |
$6K |
| 80076 |
|
1,606 |
1,323 |
$6K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
29 |
24 |
$5K |
| 81025 |
|
545 |
452 |
$3K |
| 83690 |
|
1,136 |
912 |
$3K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
50 |
39 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
84 |
70 |
$1K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
27 |
24 |
$1K |
| 81003 |
|
608 |
519 |
$1K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
87 |
69 |
$1K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
76 |
25 |
$582.40 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
82 |
64 |
$489.39 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
30 |
24 |
$483.47 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
35 |
32 |
$467.94 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,113 |
898 |
$429.46 |
| 83880 |
|
45 |
41 |
$322.93 |
| 83735 |
|
68 |
54 |
$220.10 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
906 |
734 |
$126.09 |
| 87428 |
|
82 |
74 |
$122.62 |
| 80053 |
Comprehensive metabolic panel |
233 |
217 |
$114.60 |
| 87077 |
|
25 |
24 |
$42.04 |
| 82962 |
|
191 |
96 |
$27.88 |
| A9270 |
Non-covered item or service |
5,854 |
1,887 |
$20.92 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
18 |
14 |
$13.37 |
| J2704 |
Injection, propofol, 10 mg |
408 |
379 |
$8.83 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
580 |
486 |
$3.52 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
14 |
12 |
$0.12 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
15 |
12 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
193 |
176 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
117 |
100 |
$0.00 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
346 |
313 |
$0.00 |
| A6197 |
Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing |
14 |
12 |
$0.00 |
| 83605 |
|
13 |
12 |
$0.00 |